Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI)

详细信息    查看全文

• 作者：J. Capdevila ; J. C. Galofré ; E. Grande…
• 关键词：Differentiated thyroid cancer ; Lenvatinib ; Radioactive iodine ; refractory thyroid cancer ; Review ; Sorafenib ; Targeted therapy ; Thyroid cancer
• 刊名：Clinical and Translational Oncology
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：19
• 期：3
• 页码：279-287
• 全文大小：
• 刊物主题：Oncology;
• 出版者：Springer International Publishing
• ISSN：1699-3055
• 卷排序：19

文摘

Thyroid cancer is the single most prevalent endocrine malignancy; differentiated thyroid cancer (DTC) accounts for more than 90 % of all malignancies and its incidence has been rising steadily. For more patients, surgical treatment, radioactive iodine (RAI) ablation, and thyroid-stimulating hormone (TSH) suppressive therapy achieve an overall survival (OS) rate of 97.7 % at 5 years. Nevertheless, locoregional recurrence occurs in up to 20 % and distant metastases in approximately 10 % at 10 years. Two-thirds of these patients will never be cured with radioactive iodine therapy and will become RAI-refractory, with a 3-year OS rate of less than 50 %. Over the last decade, substantial progress has been made in the management of RAI-refractory DTC. Given the controversy in some areas, the Spanish Task Force for Thyroid Cancer on behalf of Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and the Spanish Rare Cancer Working Group (GETHI) have created a national joint task force to reach a consensus addressing the most challenging aspects of management in these patients. In this way, multidisciplinary management should be mandatory and nuclear medicine targeted therapy, novel molecular targeted agents, and combinations are currently changing the natural history of RAI-refractory DTC.